Ipsen Stock Slides After Barclays Downgrade on Peak Earnings Fears

Shares of French biopharmaceutical company Ipsen (IPN) fell sharply on Tuesday, dropping 3.8% to €157.6, after analysts at Barclays downgraded the stock and warned that the company's earnings may have hit a cyclical peak.

Barclays Cites Mounting Headwinds

Barclays was the catalyst for the sell-off, cutting its rating on Ipsen to Underweight from Equalweight and reducing its price target to €155 from €170. In a note to clients, the bank argued that Ipsen's strong performance in 2026 is unlikely to be sustained due to a confluence of negative factors.

The bank highlighted three primary concerns creating downside risk for the company's 2027–2029 earnings estimates:

• Somatuline Erosion: Sales of its key drug, Somatuline, are facing accelerating erosion from intensifying generic competition.
• Pipeline Threat: A rival's drug candidate, CAM2029, could prove clinically superior to Somatuline by late 2026 or early 2027.
• Reinvestment Costs: Ipsen faces a substantial need for reinvestment to support its later-stage pipeline, which is expected to weigh on profitability.

Ad

A Chorus of Concerns

The Barclays downgrade echoes previously voiced market concerns. An earlier report from Jefferies had also flagged the competitive threat from CAM2029, estimating it could erode long-term Somatuline revenue by more than 35%. Ipsen itself acknowledged during its H1 2026 earnings call that it expected pressure on Somatuline sales in the second half of the year.

The stock's decline was amplified by a broader risk-off sentiment in the market, with major U.S. indices trading lower. After a strong run-up over the past year, which saw the stock trade in a 52-week range of €109.9–€174.0, the negative analyst action and challenging outlook made it vulnerable to a significant pullback.